Regeneron Pharmaceuticals (REGN) Intangibles (2021 - 2026)

Regeneron Pharmaceuticals has reported Intangibles for 6 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Intangibles rose 10.27% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 10.27% YoY), and the FY2025 full-year result was $1.3 billion, up 9.47% from the prior year.
• Intangibles for Q1 2026 stood at $1.3 billion, up from $1.3 billion in the prior quarter.
• The five-year high for Intangibles was $1.4 billion in Q3 2025, with the low at $155.0 million in Q2 2025.
• Average Intangibles over 5 years is $1.0 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Intangibles soared 13564.18% in 2022 and slumped 85.94% in 2025.
• Tracing REGN's Intangibles over 5 years: stood at $915.5 million in 2022, then gained by 13.45% to $1.0 billion in 2023, then rose by 10.59% to $1.1 billion in 2024, then grew by 9.47% to $1.3 billion in 2025, then gained by 2.35% to $1.3 billion in 2026.
• The last three Intangibles figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.

Peer Comparison